norelgestromin/ethinyl estradiol

(redirected from Ortho Evra)

norelgestromin/ethinyl estradiol

Evra (UK), Ortho Evra

Pharmacologic class: Estrogen

Therapeutic class: Hormone

Pregnancy risk category X

FDA Box Warning

Cigarette smoking increases risk of serious cardiovascular adverse effects from hormonal contraceptive use. Risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women older than age 35. Strongly advise women who use hormonal contraceptives not to smoke.

Risk of venous thromboembolism (VTE) among women ages 15 to 44 who used the transdermal patch compared to women who used oral contraceptives containing 30 to 35 mcg of ethinyl estradiol (EE) and either levonorgestrel or norgestimate was assessed in four U.S. case-control studies using electronic health care claims data. Odds ratios ranged from 1.2 to 2.2; one of the studies found a statistically significant increased risk of VTE for current patch users.

The pharmacokinetic (PK) profile for the transdermal patch is different from the PK profile for oral contraceptives in that it has higher steady state concentrations and lower peak concentrations. Area under the time-concentration curve and average concentration at steady state for EE are approximately 60% higher in women using the patch compared with women using an oral contraceptive containing 35 mcg of EE. In contrast, peak concentrations for EE are approximately 25% lower in women using the patch. It's unknown whether there are changes in risk of serious adverse events based on the differences in PK profiles of EE in women using the patch compared with women using oral contraceptives containing 30 to 35 mcg of EE. Increased estrogen exposure may increase risk of adverse events, including VTE.


Suppresses gonadotropin and inhibits ovulation by causing changes in cervical mucus and endometrium, thereby preventing egg implantation


Transdermal patch: 6 mg norelgestro-min and 0.75 mg ethinyl estradiol (releases 150 mcg norelgestromin and 20 mcg ethinyl estradiol q 24 hours)

Indications and dosages

To prevent pregnancy

Adults: Apply patch on day 1 of menstrual cycle (or first Sunday after period begins). Change patch weekly thereafter for 3 weeks (on same day each week), and then remove patch for fourth week. Repeat q month.


• Hypersensitivity to drug or its components

• Undiagnosed abnormal genital bleeding

• Known or suspected breast cancer or history of such cancer

• Endometrial carcinoma or other known or suspected estrogen-dependent neoplasia

• Thromboembolism, history of thromboembolic disease, known thrombophilic conditions

• Current or past cerebrovascular or coronary artery disease

• Valvular heart disease with complications

• Diabetes with vascular involvement

• Persistent blood pressure values at or above 160 mm Hg systolic or 100 mm Hg diastolic

• Headache with focal neurologic symptoms

• Cholestatic jaundice of pregnancy, jaundice with previous hormonal contraceptive use

• Acute or chronic hepatic disease with abnormal liver function

• Hepatic adenomas or carcinomas

• Major surgery with prolonged immobilization

• Known or suspected pregnancy


Use cautiously in:

• cardiovascular disease, renal disease, asthma, bone disease, migraine, lipid disorders, fibrocystic breasts, increased risk for endometrial cancer, sexually transmitted diseases

• family history of breast or genital tract cancer

• abnormal mammogram

• elderly patients (use not indicated)

• women with body weight at or abovel98 lb (90 kg)

• breastfeeding patients

• children before menarche (use not indicated).


• Apply patch to clean, dry, intact skin on buttock, abdomen, upper torso, or upper outer arm.

• Change patch on same day each week (except for fourth week, when patch is removed).

Adverse reactions

CNS: headache, dizziness, lethargy, depression, emotional lability, increased risk of cerebrovascular accident

CV: edema, hypertension, myocardial infarction, thromboembolism

EENT: contact lens intolerance, worsening of myopia or astigmatism

GI: nausea, vomiting, jaundice, abdominal cramps, bloating, anorexia, gallbladder disease, pancreatitis

GU: amenorrhea, dysmenorrhea, breakthrough bleeding, cervical erosion, vaginal candidiasis, breast tenderness, breast enlargement or secretion, menstrual cramps, libido loss, increased risk of breast or endometrial cancer

Hepatic: cholestatic jaundice, hepatic adenoma

Metabolic: hyperglycemia, hypercal-cemia, sodium and water retention

Musculoskeletal: leg cramps

Respiratory: upper respiratory infection, pulmonary embolism

Skin: acne, oily skin, increased pigmentation, urticaria, patch site reaction

Other: increased appetite, weight changes


Drug-drug. Acetaminophen, ascorbic acid, atorvastatin, miconazole (vaginal capsules): increased ethinyl estradiol blood level

Antibiotics, barbiturates, carbamazepine, fosphenytoin, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy

Corticosteroids: enhanced corticosteroid effects

Cyclosporine: increased risk of cyclosporine toxicity

CYP3A4 inhibitors (such as ketocona-zole, itraconazole): increased hormone level

Dantrolene, other hepatotoxic drugs: increased risk of hepatotoxicity

Insulin, oral hypoglycemics, warfarin: altered requirements for these drugs Protease inhibitors: increased contraceptive metabolism

Tamoxifen: interference with tamoxifen effects

Drug-diagnostic tests. Antithrombin III, folate, low-density lipoproteins, pyri-doxine, total cholesterol, urine pregnane-diol: decreased levels

Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phos-pholipids; prolactin; prothrombin; sodium; triglycerides: increased levels

Metyrapone test: false decrease Thyroid function tests: false interpretation

Drug-food. Caffeine: increased blood caffeine level

Drug-herbs. Black cohosh: increased adverse drug effects

Red clover: interference with hormonal therapy

Saw palmetto: antiestrogenic effects St. John's wort: decreased drug blood level and effects

Drug-behaviors. Smoking (15 or more cigarettes daily): increased risk of adverse cardiovascular reactions

Patient monitoring

• Evaluate menstrual pattern.

Monitor blood pressure. Watch for signs and symptoms of thrombo-embolic disease (swelling or warmth in calf, sudden chest pain, shortness of breath).

• Check blood glucose level in diabetic patient.

Patient teaching

• Instruct patient to start using patch on first day of menstrual period or on first Sunday after period starts. Advise her to use calendar to keep track of which day each week to change patch.

• Tell patient to remove patch during fourth week of each cycle. Explain that she will have bleeding that week.

• Advise patient to check daily to ensure that patch is attached firmly to skin. Explain that if patch is detached for 1 day or less, she should try to reattach it more firmly. If patch is detached for more than 1 day or for an unknown length of time, she should start with new patch and new calendar.

• Instruct patient to use alternative contraception during first week of patch use.

Inform patient that smoking while using patch increases risk of thrombo-embolic disease and other serious cardiovascular reactions. Stress importance of not smoking. Tell her to immediately report swelling or warmth in calf, chest pain, or shortness of breath.

• Advise breastfeeding patient to use other forms of contraception until she has completely weaned her infant.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
Agile Therapeutics announced topline results from a comparative wear study testing the adhesion of Twirla compared to that of Xulane, the generic version of the previously marketed Ortho Evra contraceptive patch, a product the FDA considers to have acceptable adhesion.
The company added XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day) is the generic version of Janssen Pharmaceuticals' ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).
The contraceptive Ortho Evra is a transdermal (through the skin) patch approved by the FDA in 2001 that contains ethinyl estradiol and the progesterone norelgestromin.
The Food and Drug Administration denied a request from the consumer advocacy group Public Citizen to begin a phased withdrawal of the transdermal contraceptive patch Ortho Evra (norelgestromin/ethinyl estradiol).
Hat was told to me in a church-sanctioned class can be heard elsewhere: that any woman using a hormonal method of birth control--including oral contraceptives, Depo-Provera and Lunelle shots, NuvaRings, Ortho Evra patches and IUDS--can induce abortion.
From 2002 through 2006, at least 40 women died using its weekly Ortho Evra patch, most from blood clots.
(New Brunswick NJ) has spent at least $68.7 million to settle hundreds of lawsuits filed by women who suffered blood clots, heart attacks or strokes after using the company's Ortho Evra birth-control patch, court records show.
The transdermal patch (Ortho Evra) is another effective contraceptive option that is especially appealing to women who don't want to remember to take a pill every day, Dr.
Inadequate hormonal protection included 2 situations: recent initiation of a hormonal method when it was too soon to be effective, and a gap in coverage due to missed pills, forgetting to put on a new Ortho Evra Patch, or missed Depo-Provera shot.
The case involved Cincinnati property manager Melisa Arbino, who claimed that the Ortho Evra Birth Control Patch made by Johnson & Johnson caused permanent physical damage and jeopardized her fertility.
Arbino sued Johnson & Johnson in federal district court for damages after suffering medical problems she alleged were caused by the Ortho Evra birth control patch.
Ortho Evra (norelgestromin/ethinyl estradiol transdermal system, Ortho-McNeil Pharmaceuticals Inc.)--better known as "the patch"--is a transdermal patch that adheres to certain areas of the body once weekly for 3 weeks, followed by 1 week without a patch.